Cargando…
Health state utilities for non small cell lung cancer
BACKGROUND: Existing reports of utility values for metastatic non-small cell lung cancer (NSCLC) vary quite widely and are not all suitable for use in submissions in the UK. The aim of this study was to elicit UK societal based utility values for different stages of NSCLC and different grade III-IV...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579282/ https://www.ncbi.nlm.nih.gov/pubmed/18939982 http://dx.doi.org/10.1186/1477-7525-6-84 |
_version_ | 1782160562906464256 |
---|---|
author | Nafees, Beenish Stafford, Megan Gavriel, Sonia Bhalla, Shkun Watkins, Jessamy |
author_facet | Nafees, Beenish Stafford, Megan Gavriel, Sonia Bhalla, Shkun Watkins, Jessamy |
author_sort | Nafees, Beenish |
collection | PubMed |
description | BACKGROUND: Existing reports of utility values for metastatic non-small cell lung cancer (NSCLC) vary quite widely and are not all suitable for use in submissions in the UK. The aim of this study was to elicit UK societal based utility values for different stages of NSCLC and different grade III-IV toxicities commonly associated with chemotherapy treatments. Toxicities included neutropenia, febrile neutropenia, fatigue, diarrhoea, nausea and vomiting, rash and hair loss. METHODS: Existing health state descriptions of metastatic breast cancer were revised to make them suitable as descriptions of metastatic NSCLC patients on second-line treatment. The existing health states were used in cognitive debrief interviews with oncologists (n = 5) and oncology specialist nurses (n = 5). Changes were made as suggested by the clinical experts. The resulting health states (n = 17) were piloted and used in a societal based valuation study (n = 100). Participants rated half of the total health states in a standard gamble interview to derive health state utility scores. Data were analysed using a mixed model analysis. RESULTS: Each health state described the symptom burden of disease and impact on different levels of functioning (physical, emotional, sexual, and social). The disutility related to each disease state and toxicity was estimated and were combined to give health state values. All disease states and toxicities were independent significant predictors of utility (p < 0.001). Stable disease with no toxicity (our base state) had a utility value of 0.653. Utility scores ranged from 0.673 (responding disease with no toxicity) to 0.473 for progressive disease. CONCLUSION: This study reflects the value that society place on the avoidance of disease progression and severe toxicities in NSCLC. |
format | Text |
id | pubmed-2579282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-25792822008-11-05 Health state utilities for non small cell lung cancer Nafees, Beenish Stafford, Megan Gavriel, Sonia Bhalla, Shkun Watkins, Jessamy Health Qual Life Outcomes Research BACKGROUND: Existing reports of utility values for metastatic non-small cell lung cancer (NSCLC) vary quite widely and are not all suitable for use in submissions in the UK. The aim of this study was to elicit UK societal based utility values for different stages of NSCLC and different grade III-IV toxicities commonly associated with chemotherapy treatments. Toxicities included neutropenia, febrile neutropenia, fatigue, diarrhoea, nausea and vomiting, rash and hair loss. METHODS: Existing health state descriptions of metastatic breast cancer were revised to make them suitable as descriptions of metastatic NSCLC patients on second-line treatment. The existing health states were used in cognitive debrief interviews with oncologists (n = 5) and oncology specialist nurses (n = 5). Changes were made as suggested by the clinical experts. The resulting health states (n = 17) were piloted and used in a societal based valuation study (n = 100). Participants rated half of the total health states in a standard gamble interview to derive health state utility scores. Data were analysed using a mixed model analysis. RESULTS: Each health state described the symptom burden of disease and impact on different levels of functioning (physical, emotional, sexual, and social). The disutility related to each disease state and toxicity was estimated and were combined to give health state values. All disease states and toxicities were independent significant predictors of utility (p < 0.001). Stable disease with no toxicity (our base state) had a utility value of 0.653. Utility scores ranged from 0.673 (responding disease with no toxicity) to 0.473 for progressive disease. CONCLUSION: This study reflects the value that society place on the avoidance of disease progression and severe toxicities in NSCLC. BioMed Central 2008-10-21 /pmc/articles/PMC2579282/ /pubmed/18939982 http://dx.doi.org/10.1186/1477-7525-6-84 Text en Copyright © 2008 Nafees et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Nafees, Beenish Stafford, Megan Gavriel, Sonia Bhalla, Shkun Watkins, Jessamy Health state utilities for non small cell lung cancer |
title | Health state utilities for non small cell lung cancer |
title_full | Health state utilities for non small cell lung cancer |
title_fullStr | Health state utilities for non small cell lung cancer |
title_full_unstemmed | Health state utilities for non small cell lung cancer |
title_short | Health state utilities for non small cell lung cancer |
title_sort | health state utilities for non small cell lung cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579282/ https://www.ncbi.nlm.nih.gov/pubmed/18939982 http://dx.doi.org/10.1186/1477-7525-6-84 |
work_keys_str_mv | AT nafeesbeenish healthstateutilitiesfornonsmallcelllungcancer AT staffordmegan healthstateutilitiesfornonsmallcelllungcancer AT gavrielsonia healthstateutilitiesfornonsmallcelllungcancer AT bhallashkun healthstateutilitiesfornonsmallcelllungcancer AT watkinsjessamy healthstateutilitiesfornonsmallcelllungcancer |